[{"address1": "10955 Vista Sorrento Parkway", "address2": "Suite 200", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 751 4493", "website": "https://www.januxrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Dr. David Alan Campbell Ph.D.", "age": 63, "title": "President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 1037500, "exercisedValue": 0, "unexercisedValue": 9922011}, {"maxAge": 1, "name": "Mr. Charles M. Winter", "age": 54, "title": "Chief Technical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 590400, "exercisedValue": 0, "unexercisedValue": 460878}, {"maxAge": 1, "name": "Mr. Byron  Robinson J.D., Ph.D.", "age": 58, "title": "Chief Strategy Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 723000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matt  Whitmire", "title": "Vice President of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Dobek", "age": 34, "title": "Principal Accounting Officer & VP of Accounting", "yearBorn": 1989, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tommy  Diraimondo Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Pennington", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Brenda  Van Vreeswyk", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andy Hollman Meyer", "age": 39, "title": "Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1726617600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 48.32, "open": 50.1, "dayLow": 48.7445, "dayHigh": 50.97, "regularMarketPreviousClose": 48.32, "regularMarketOpen": 50.1, "regularMarketDayLow": 48.7445, "regularMarketDayHigh": 50.97, "beta": 3.566, "forwardPE": -31.043478, "volume": 745543, "regularMarketVolume": 745543, "averageVolume": 595260, "averageVolume10days": 688540, "averageDailyVolume10Day": 688540, "bid": 49.87, "ask": 50.19, "bidSize": 200, "askSize": 100, "marketCap": 2607181568, "fiftyTwoWeekLow": 5.65, "fiftyTwoWeekHigh": 65.6, "priceToSalesTrailing12Months": 172.35284, "fiftyDayAverage": 43.3396, "twoHundredDayAverage": 34.631775, "currency": "USD", "enterpriseValue": 1984594560, "profitMargins": -2.91168, "floatShares": 32173654, "sharesOutstanding": 52164500, "sharesShort": 3315464, "sharesShortPriorMonth": 3663764, "sharesShortPreviousMonthDate": 1722384000, "dateShortInterest": 1724976000, "sharesPercentSharesOut": 0.0636, "heldPercentInsiders": 0.09325, "heldPercentInstitutions": 0.98393, "shortRatio": 6.61, "shortPercentOfFloat": 0.12560001, "impliedSharesOutstanding": 52164500, "bookValue": 12.608, "priceToBook": 3.9641497, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -44045000, "trailingEps": -0.88, "forwardEps": -1.61, "pegRatio": -0.28, "enterpriseToRevenue": 131.196, "enterpriseToEbitda": -31.075, "52WeekChange": 4.20625, "SandP52WeekChange": 0.32258344, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "JANX", "underlyingSymbol": "JANX", "shortName": "Janux Therapeutics, Inc.", "longName": "Janux Therapeutics, Inc.", "firstTradeDateEpochUtc": 1623418200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3a638123-d3da-3133-96c7-e6e8cabf84b3", "messageBoardId": "finmb_676965261", "gmtOffSetMilliseconds": -14400000, "currentPrice": 49.98, "targetHighPrice": 100.0, "targetLowPrice": 42.0, "targetMeanPrice": 67.5, "targetMedianPrice": 66.5, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 646292992, "totalCashPerShare": 12.39, "ebitda": -63864000, "totalDebt": 23820000, "quickRatio": 57.025, "currentRatio": 57.336, "totalRevenue": 15127000, "debtToEquity": 3.622, "revenuePerShare": 0.309, "returnOnAssets": -0.07979, "returnOnEquity": -0.09203, "freeCashflow": -36217124, "operatingCashflow": -46468000, "revenueGrowth": 7.417, "grossMargins": -2.51035, "operatingMargins": -1.55356, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-20"}]